Gene therapy protects against motor neuron disease in rats
University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...
Science Daily6h
Using CRISPR to decipher whether gene variants lead to cancer
Researchers have combined two gene editing methods. This enables them to quickly investigate the significance of many genetic mutations involved in the development and treatment of cancer.
GlobalData on MSN1d
FDA delays priority review of Neurotech’s eye cell therapy implant
The US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...
The Tandem Meetings of ASTCT and CIBMTR Return to Hawai’i From February 12-15, 2025
ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.
New Atlas3d
RNA therapy an effective alternative to lifelong, painful eye injections
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
The Week18h
How innovations in CAR T-Cell therapy pave way for broader and safer cancer treatment
To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...
Becker's Hospital Review6d
Sickle cell patient dies in gene-therapy trial
Beam Therapeutics' early clinical data shows promising results for sickle cell disease treatment using CRISPR gene editing tool. One patient died ...
University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first
Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...
BioSpace7d
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
BioSpace1d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
Armed robbery in Revesby10h
Gene Therapy Shields Rats from Motor Neuron Disease
University of Wisconsin-Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...